Up next

Autoplay

ASCO 2023 Highlights on nivolumab in advanced stage classic Hodgkin Lymphoma: the SWOG S1826 study

0 Views • 07/09/23
Share
Embed
administrator
administrator
Subscribers
0

Reporting from ASCO 2023, Alex Herrera discusses the results from the SWOG study on nivolumab in advanced stage classic Hodgkin Lymphoma.

Abstract: LBA4 - SWOG S1826, a randomized study of nivolumab(N)-AVD versus brentuximab vedotin(BV)-AVD in advanced stage (AS) classic Hodgkin lymphoma (HL), presented by Alex Herrera.

The ESMO Educational Videos series features renowned experts in oncology sharing their knowledge on a variety of subjects. Full series here https://oncologypro.esmo.org/o....ncology-news/esmo-vi

Produced by the European Society for Medical Oncology
http://www.esmo.org

Show more
0 Comments sort Sort By
Facebook Comments

Up next

Autoplay